Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
NCT03042312
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
71
Enrollment
INDUSTRY
Sponsor class
Stopped
Recruitment was stopped before the target sample size was achieved.
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG:
177Lu-PSMA-617
Sponsor
Endocyte